Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company

InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable

Fineline Cube May 14, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) released its Q1 2025 financial report, recording...

Drug Policy / Regulatory

NMPA Releases 92nd Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube May 14, 2025

The National Medical Products Administration (NMPA) has released the 92nd batch of reference drugs for...

Company Deals

Gan & Lee Pharmaceuticals Signs PDP Agreement with Brazilian Health Ministry

Fineline Cube May 14, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) announced the signing of Parcerias para o Desenvolvimento Produtivo...

Company Drug

Zelgen Biopharmaceuticals Submits New Indication Application for Jacktinib in Severe Alopecia Areata

Fineline Cube May 14, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has submitted a new...

Company Deals

Meheco Acquires Golden Harvest for E-commerce Expansion

Fineline Cube May 14, 2025

China Meheco Group Co., Ltd (SHA: 600056) announced the acquisition of 100% stake in Beijing...

Company

JD Healthcare Reports 25.5% Revenue Growth in Q1 2025

Fineline Cube May 14, 2025

JD Healthcare (HKG: 6618), a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), released its...

Company Drug

Ocumension Therapeutics Receives Approval for OT-703 Real-World Study in China

Fineline Cube May 14, 2025

Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) announced that it has received approval in China...

Company

Legend Biotech’s Q1 2025 Results Highlight Carvykti Sales Growth

Fineline Cube May 14, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q1 2025 financial report, highlighting significant revenue...

Company Deals

Sanyou Biopharmaceuticals and TransReco Biotechnology Partner to Advance Novel Drug Formulations

Fineline Cube May 14, 2025

China-based Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and TransReco (Wenzhou) Biotechnology Co., Ltd. announced a strategic...

Company Deals

Novo Nordisk Partners with PingAn Good Doctor to Promote Scientific Weight Loss in China

Fineline Cube May 14, 2025

Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) has formed a strategic partnership with China’s Ping...

Company Drug

BRL Medicine Reports Positive Results for TyU19 in Refractory SLE Trial

Fineline Cube May 14, 2025

Shanghai-based BRL Medicine Inc. announced positive results from an investigator-initiated trial (ITT) evaluating its allogeneic...

Company Deals

InnoCare Pharma Partners with Westlake University for Innovative Drug Research

Fineline Cube May 14, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced a strategic partnership agreement with Westlake...

Company Drug

Betta Pharmaceuticals Secures Macau Approval for Ensartinib

Fineline Cube May 13, 2025

China-based Betta Pharmaceuticals (SHE: 300558) announced a market approval filing in Macau for its ensartinib,...

Company Deals

OYMotion Technologies Secures RMB 100 Million in Series B++ Funding for Exoskeleton Robots

Fineline Cube May 13, 2025

Shanghai-based OYMotion Technologies Co., Ltd, a high-tech company specializing in brain-computer interface and robotics technology,...

Company Deals

Genentech to Invest Over $700 Million in North Carolina Drug Manufacturing Facility

Fineline Cube May 13, 2025

Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), announced plans to invest...

Company Drug

Huadong Medicine Presents DR10624 Study Results for Obesity and Hypertriglyceridemia at EASL 2025

Fineline Cube May 13, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced the first presentation of results from its...

Company

Teva Announces 8% Workforce Reduction to Achieve $700 Million Cost-Saving Goal

Fineline Cube May 13, 2025

Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has disclosed plans to reduce its workforce by...

Company Deals Drug

Formosa Pharmaceuticals Signs Licensing Deal with Laboratorios Saval for APP13007

Fineline Cube May 13, 2025

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with Laboratorios Saval, granting the Chilean...

Company Deals

Hybio Partners with iCarbonX to Develop Triple Agonist for Metabolic Diseases

Fineline Cube May 13, 2025

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced a strategic partnership with compatriot firm iCarbonX...

Company Deals

Tenacia Partners with TSH Biopharm for Ztalmy Commercialization in Taiwan

Fineline Cube May 13, 2025

Tenacia Biotechnology, a central nervous system (CNS) specialist backed by Bain Capital, has entered into...

Posts pagination

1 … 215 216 217 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.